Kaylee Terrell
Family · Oklahoma City, OKNPI 1801484936
Payments from drug & device makers
Across 239 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$503
- Boston Scientific$282
- Boehringer Ingelheim$269
- Pfizer$225
- Lilly USA, LLC$186
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,07998%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,044 |
| AbbVie | 42 | $503 |
| Boston Scientific | 15 | $282 |
| Boehringer Ingelheim | 16 | $269 |
| Pfizer | 13 | $225 |
| Lilly USA, LLC | 11 | $186 |
| Novo Nordisk | 11 | $176 |
| Astellas Pharma US Inc | 5 | $150 |
| Amgen | 8 | $137 |
| GSK | 7 | $121 |
| Novartis | 5 | $115 |
| Johnson & Johnson(2 entities) | 5 | $94 |
| Corcept Therapeutics | 3 | $73 |
| Exact Sciences | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Mannkind Corporation | 4 | $61 |
| Dexcom, Inc. | 3 | $57 |
| Viiv Healthcare Company | 2 | $54 |
| Mylan Specialty L.p. | 2 | $44 |
| Baxter Healthcare | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Merck | 2 | $32 |
| Electromed, Inc. | 2 | $31 |
| Inogen, Inc. | 2 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$4,164 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $85,848 |
| MounjaroTirzepatide | 41 | $57,744 |
| JardianceEmpagliflozin | 38 | $51,855 |
| VraylarCariprazine Hcl | 17 | $25,565 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $25,308 |
| EliquisApixaban | 23 | $21,294 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $14,633 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,640 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $3,517 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,764 |
| Omeprazole | 59 | $1,485 |
| Levothyroxine Sodium | 108 | $1,409 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,099 |
| Atorvastatin Calcium | 114 | $1,059 |
| Duloxetine Hcl | 26 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $176 | $85,84875 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $269 | $66,48850 claims |
| Lilly USA, LLCMounjaro | $186 | $57,74441 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $121 | $32,94851 claims |
| AbbVieVraylar | $503 | $25,56517 claims |
| PfizerEliquis | $225 | $21,29423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.